Centessa Q4 net loss $43.2M; cash $393.6M; SerpinPC, LB101, ORX750 progress

Centessa Pharmaceuticals plc

Cash and cash equivalents $393.6M as of Dec 31, 2022; expected to fund operations into 2026.
Net loss attributable to ordinary shareholders $43.2M for Q4 2022 vs $60.8M in Q4 2021.
SerpinPC registrational program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected in 2023.
First subject dosed in Phase 1/2a trial of LB101 (PD-L1xCD47 LockBody) for solid tumors.
ORX750 nominated as product candidate for narcolepsy; preclinical data expected at scientific meeting in 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Centessa Pharmaceuticals plc reported financial results for the fourth quarter and full-year ended December 31, 2022.

Period: the fourth quarter and full-year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended December 31, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001847903-23-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.